Adial Pharmaceuticals (ADIL) announced a “positive” response from the U.S. FDA regarding its proposed in vitro bridging strategy for AD04. The FDA’s feedback follows Adial’s submission on ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

GLEN ALLEN, Va. - Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a biopharmaceutical company specializing in addiction treatment with a current market capitalization of $5 million, has been granted a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

GLEN ALLEN, Va., March 04, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing ...

GLEN ALLEN, Va., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical ...

The FDA agreed with Adial’s proposed 505(b)(2) bridging strategy, supporting AD04's progression to Phase 3 trials in 2025. Adial’s AD04-103 study shows bioavailability, dose proportionality ...

(RTTNews) - Adial Pharmaceuticals, Inc. (ADIL), a clinical-stage biopharmaceutical company, announced on Tuesday that it has received positive feedback from the U.S. Food and Drug Administration ...

(RTTNews) - Adial Pharmaceuticals, Inc. (ADIL) announced the issuance of a new U.S. patent No. 12,226,401 expanding its genetic-based approach to treating and diagnosing alcohol use disorder or ...

FDA feedback confirms Adial’s proposed in vitro bridging strategy to the Phase 3 formulation to fulfill the bridging requirement for the 505(b)(2) regulatory registration pathway for approval ...